Patents by Inventor Cheuk Lun Leung

Cheuk Lun Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF
    Publication number: 20240262914
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Application
    Filed: March 19, 2024
    Publication date: August 8, 2024
    Inventors: Bing GONG, Rachel RENNARD, Amanda Frank OLIPHANT, Cheuk Lun LEUNG, Benjamin Jacob WOLF, Ugur ESKIOCAK, Pearl BAKHRU, Diana I. ALBU
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20240181050
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: August 4, 2023
    Publication date: June 6, 2024
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Antigen binding molecules targeting SARS-CoV-2
    Patent number: 11981725
    Abstract: The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: May 14, 2024
    Assignee: Flagship Pioneering Innovations VI, LLC
    Inventors: Gevorg Grigoryan, John Ingraham, Cheuk Lun Leung, Ross Steven Federman, Robin Jeffrey Green, Alexis Hiram Ramos, Jenhan Tao
  • Multispecific binding constructs against checkpoint molecules and uses thereof
    Patent number: 11970538
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: April 30, 2024
    Assignee: COMPASS THERAPEUTICS LLC
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • Antigen Binding Molecules Targeting SARS-CoV-2
    Publication number: 20230295275
    Abstract: The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).
    Type: Application
    Filed: January 6, 2023
    Publication date: September 21, 2023
    Inventors: Gevorg Grigoryan, John Ingraham, Cheuk Lun Leung, Ross Steven Federman, Robin Jeffrey Green, Alexis Hiram Ramos, Jenhan Tao
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 11752207
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: September 12, 2023
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Antigen Binding Molecules Targeting SARS-CoV-2
    Publication number: 20230279081
    Abstract: The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).
    Type: Application
    Filed: January 6, 2023
    Publication date: September 7, 2023
    Inventors: Gevorg Grigoryan, John Ingraham, Cheuk Lun Leung, Ross Steven Federman, Robin Jeffery Green, Vincent Xue, Craig Owen MacKenzie
  • MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF
    Publication number: 20210284736
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 16, 2021
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • Multispecific binding constructs against checkpoint molecules and uses thereof
    Patent number: 11046769
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 29, 2021
    Assignee: COMPASS THERAPEUTICS LLC
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20200306374
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: June 8, 2020
    Publication date: October 1, 2020
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10716851
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: July 21, 2020
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF
    Publication number: 20200181266
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Application
    Filed: November 13, 2019
    Publication date: June 11, 2020
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20200046833
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 13, 2020
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10434175
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: October 8, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190269776
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 5, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190224315
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10350292
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: July 16, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279040
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279039
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279038
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak